Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)
Completed
Merck Sharp & Dohme Corp.
Phase 3
2015-08-21
The study will evaluate the efficacy and safety of imipenem+cilastatin/relebactam (MK-7655A)
versus colistimethate sodium+imipenem+cilastatin in the treatment of imipenem-resistant
bacterial infections. Infections evaluated in the study will be hospital-acquired bacterial
pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), complicated
intra-abdominal infection (cIAI), and complicated urinary tract infection (cUTI).
Imipenem, Cilastatin Sodium, and Relebactam Monohydrate for the Treatment of Cancer Patients With Febrile Neutropenia
Not yet recruiting
M.D. Anderson Cancer Center
Phase 2
2021-08-10
This phase II trial studies the effect of imipenem-relebactam in treating patients with
cancer who have a fever due to low white blood cell counts (febrile neutropenia). In this
study, imipenem-relebactam will be compared to the standard-of-care treatment (cefepime,
meropenem, or piperacillin/tazobactam) for the treatment of febrile neutropenia.
Imipenem-relebactam is used to treat infections. Giving imipenem-relebactam may help to
control febrile neutropenia in patients with cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
